Amgen Inc (AMGN)

NASDAQ
Currency in USD
289.63
-0.42(-0.14%)
Closed·
After Hours
289.65+0.02(+0.01%)
·
AMGN Scorecard
Full Analysis
High shareholder yield
AMGN is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
286.60291.87
52 wk Range
253.30346.85
Key Statistics
Edit
Prev. Close
290.05
Open
290.79
Day's Range
286.6-291.87
52 wk Range
253.3-346.85
Volume
2.03M
Average Volume (3m)
2.97M
1-Year Change
-4.36%
Book Value / Share
11.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
314.70
Upside
+8.65%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years

Amgen Inc News & Analysis

Show more

Amgen Inc Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Employees
28000

Amgen Inc SWOT Analysis


Pipeline Potential
Explore Amgen's robust product pipeline, including MariTide for obesity treatment and promising oncology candidates, driving future growth prospects
Financial Health
Amgen's strong Q1 2025 results, with revenue of $9.09 billion and EPS of $5.31, underscore its solid financial position and market leadership
Market Dynamics
Delve into Amgen's competitive landscape, including its biosimilars strategy and challenges in the rare disease segment post-Horizon acquisition
Analyst Outlook
Analyst price targets range from $305 to $346, reflecting varied perspectives on Amgen's growth potential and market positioning
Read full SWOT analysis

Amgen Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $4.90 beat forecast by 14.2%; revenue reached $8.15 billion, up 9% year-over-year
  • Biosimilars portfolio grew 35%, contributing $700 million; 14 medicines saw double-digit sales growth
  • Stock fell 2.49% post-earnings despite beat; company maintains 3.27% dividend yield
  • 2025 guidance: revenue $34.3-35.7 billion, non-GAAP EPS $20-21.2; R&D expenses to increase 20%
  • Executives emphasize long-term innovation, growth, and value creation for patients and shareholders
Last Updated: 2025-05-01, 05:54 p/m
Read Full Transcript

Compare AMGN to Peers and Sector

Metrics to compare
AMGN
Peers
Sector
Relationship
P/E Ratio
26.3x−2.9x−0.4x
PEG Ratio
0.46−0.070.00
Price/Book
25.1x1.7x2.6x
Price / LTM Sales
4.6x3.1x3.0x
Upside (Analyst Target)
10.7%46.3%52.3%
Fair Value Upside
Unlock25.5%9.4%Unlock

Analyst Ratings

15 Buy
15 Hold
3 Sell
Ratings:
33 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 314.70
(+8.65% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 11.04%
Dividend Yield
3.28%
Industry Median 1.73%
Annualized payout
9.52
Paid quarterly
5-Years Growth
+8.94%
Growth Streak

Earnings

Latest Release
May 01, 2025
EPS / Forecast
4.90 / 4.29
Revenue / Forecast
8.15B / 8.09B
EPS Revisions
Last 90 days

AMGN Income Statement

People Also Watch

52.26
ON
-1.28%
307.20
UNH
-0.54%
513.58
REGN
+0.93%
100.82
FTNT
-2.00%

FAQ

What Is the Amgen (AMGN) Stock Price Today?

The Amgen stock price today is 289.63

What Stock Exchange Does Amgen Trade On?

Amgen is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Amgen?

The stock symbol for Amgen is "AMGN."

Does Amgen Pay Dividends? What’s The Current Dividend Yield?

The Amgen dividend yield is 3.29%.

What Is the Amgen Market Cap?

As of today, Amgen market cap is 155.66B.

What Is Amgen's Earnings Per Share (TTM)?

The Amgen EPS (TTM) is 11.04.

When Is the Next Amgen Earnings Date?

Amgen will release its next earnings report on Aug 05, 2025.

From a Technical Analysis Perspective, Is AMGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Amgen Stock Split?

Amgen has split 5 times.

How Many Employees Does Amgen Have?

Amgen has 28000 employees.

What is the current trading status of Amgen (AMGN)?

As of Jun 19, 2025, Amgen (AMGN) is trading at a price of 289.63, with a previous close of 290.05. The stock has fluctuated within a day range of 286.60 to 291.87, while its 52-week range spans from 253.30 to 346.85.

What Is Amgen (AMGN) Price Target According to Analysts?

The average 12-month price target for Amgen is USD314.69679, with a high estimate of USD400 and a low estimate of USD185. 15 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +8.65% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.